Market Overview

Celgene To Surge By Double-Digits After Big Tumble, Vetr Crowd Says

Related CELG
January's Market Bounce Resulted In Some Unexpected Retail Trading Trends
Investor Movement Index January Summary
Maryland strikes out in reviving drug price-gouging law (Seeking Alpha)

Shares of Celgene Corporation (NASDAQ: CELG) have had ups and downs this year, but have ultimately lost roughly 11 percent since January.

It seems like the Vetr crowd believes this has created an attractive entry point, as the stock looks ripe for a rebound. This is evidenced by the crowd’s average price target of $120.45, which implies a potential return of approximately 12.6 percent from current valuations.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided to upgrade its rating on shares of Celgene on Wednesday, from 4.0 (Buy) to 4.5 stars (Strong Buy) — out of a possible five-star rating.

It should be noted that, relatively in accordance with the new rating, 78 percent of the crowd’s ratings are bullish at the time.

Latest Ratings for CELG

Feb 2019JefferiesDowngradesBuyHold
Jan 2019BairdUpgradesNeutralOutperform
Jan 2019Wells FargoMaintainsMarket PerformMarket Perform

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: VetrUpgrades Price Target Crowdsourcing Analyst Ratings General


Related Articles (CELG)

View Comments and Join the Discussion!

H&R Block Q1 Report Leaves Investors With Few Questions Answered

Oppenheimer Bullish On Pure Storage, Upgrades To Outperform